- Stocks
- Pharma & Healthcare
- Venmax Drugs
Venmax Drugs share price
NSE: VENMAXPharma & HealthcareDrug Manufacturers - Specialty & Generic
Venmax Drugs at a glance
With a market capitalisation of ₹17 Cr, it ranks 3677th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −0.2% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹4 Cr (+1,093.9% year on year) and net profit ₹0 Cr (−85.9%), on a standalone basis. Promoters held 10.46% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹17 CrRank 3677 on NSE
- Price to book
- 3.39×FY25
- EPS (TTM)
- ₹0.37to Q4 FY26
- ROE
- −0.2%FY25
- ROCE
- −0.3%FY25
- Debt to equity
- 0.01FY25
- Net profit margin
- −1.3%FY25
- Book value / share
- ₹8.42FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Venmax Drugs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr |
| Revenue YoY | — | — | — | — | +1,110.0% | +676.5% | +675.0% | +1,093.9% |
| Net profit | ₹0 Cr | −₹0 Cr | −₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | −50.0% | — | −1,766.7% | +1,460.0% | +300.0% | — | — | −85.9% |
| Net margin | 10.0% | −176.5% | −250.0% | 236.4% | 3.3% | 1.5% | 1.9% | 2.8% |
| EPS | ₹0.02 | −₹0.58 | −₹0.95 | ₹1.48 | ₹0.07 | ₹0.05 | ₹0.05 | ₹0.20 |
Venmax Drugs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Operating profit | −₹0 Cr | −₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
| Net profit | −₹0 Cr | −₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
| EPS (₹) | −₹0.52 | −₹0.31 | ₹3.52 | ₹0.43 | ₹0.12 | −₹0.02 |
| Cash from operations | −₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | −₹2 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | −₹3 Cr | −₹3 Cr | −₹1 Cr | −₹1 Cr | −₹1 Cr | ₹4 Cr |
Venmax Drugs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 23.13% | 23.13% | 23.13% | 15.14% | 13.80% | 10.46% |
| Non-institutions | 76.72% | 76.87% | 76.87% | 84.86% | 86.20% | 89.54% |
Venmax Drugs vs peers
The listed Pharma & Healthcare companies nearest to Venmax Drugs by market capitalisation.
Ask anything about Venmax Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against VENMAX's own history. Try: “Why has VENMAX moved over the last three months?” · “Backtest a 50-day moving-average crossover on VENMAX over five years” · “Compare VENMAX with DESHRAK on margins and valuation”
Frequently asked questions about Venmax Drugs
What is the market cap of Venmax Drugs?
Venmax Drugs' market capitalisation is ₹17 Cr (₹17 Cr) at the 22 Oct 2026 close, ranking 3677th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Venmax Drugs?
Return on equity was −0.2% in FY25 and return on capital employed was −0.3% in FY25 (standalone figures).
Is Venmax Drugs a debt-free company?
Venmax Drugs is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.
What were Venmax Drugs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Venmax Drugs reported revenue of ₹4 Cr, +1,093.9% year on year, and net profit of ₹0 Cr, −85.9% year on year.
What is the shareholding pattern of Venmax Drugs?
As of 30 Jun 2026: promoters 10.46%, non-institutions 89.54%.
Who are Venmax Drugs' competitors?
The listed Pharma & Healthcare companies closest to Venmax Drugs by market cap are Desh Rakshak, Nidan Lab, Vanta Bioscienc, Zenith Health, Family Care Hos and Colinz Labs.
Is Venmax Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Venmax Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VENMAX against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text